4697-36-3 Usage
Description
Carbenicillin is a penicillin antibiotic characterized by a 6beta-2-carboxy-2-phenylacetamido side-chain. It is known for its effectiveness in treating various bacterial infections due to its potent antibacterial properties.
Uses
Used in Pharmaceutical Industry:
Carbenicillin is used as an antibiotic for treating bacterial infections. Its application is primarily due to its ability to inhibit bacterial cell wall synthesis, leading to the destruction of the bacterial cell.
Used in Medical Treatments:
In the medical field, Carbenicillin is used as a therapeutic agent for patients suffering from a range of bacterial infections. Its effectiveness in combating bacteria makes it a valuable tool in the treatment of various illnesses.
Brand Names:
Some of the brand names under which Carbenicillin is marketed in the United States include Geopen (Roerig) and Pyopen (GlaxoSmithKline). Carbenicillin indanyl sodium is also available under the brand name Geocillin.
Originator
Pyopen,Beecham,Switz.,1968
Indications
Carbenicillin has a broad spectrum of antibacterial use with respect to Gram-negative and
Gram-positive microorganisms. However, using this drug for infections caused by Grampositive microorganisms is pointless. It is used for diseases such as urinary tract infections,
septicemia, endocarditis, meningitis, osteomelitis, peritonitis, purulent otitis, infected
wounds, infected burns, and so on that are caused by Gram-negative microorganisms which
are sensitive to such antibiotics. Synonyms of this drug are carindapen, pyopen, geopen,
gripenin, and others.
Manufacturing Process
The required monobenzyl phenylmalonate, MP 68°C, was prepared by treating
a mixture of phenylmalonic acid (18 g) and benzyl alcohol (13 g) in carbon
tetrachloride (80 ml) with dry hydrogen chloride.Monobenzyl phenylmalonate (13.3 g) in dry benzene (100 ml) was refluxed with thionyl chloride (6.45 g) for 90 minutes, then concentrated in vacuo. The
residual oil was dissolved in dry acetone (50 ml) and added to a stirred, ice-cooled solution of 6-aminopenicillanic acid (9.7 g) in N sodium bicarbonate
solution (135 ml), water (150 ml), and acetone (300 ml). The mixture was
stirred for 30 minutes at 0°C and then for 90 minutes at room temperature,
then concentrated under reduced pressure to remove acetone. The aqueous
solution was brought to pH 2 with dilute hydrochloric acid and extracted with
ether (3 x 100 ml). The ether solution was washed with water and then itself
extracted with sufficient N sodium bicarbonate solution to give an aqueous
phase of pH 7.5. The aqueous layer was separated and evaporated at low
temperature and pressure to leave the impure sodium salt of alpha-
(benzyloxycarbonyl) benzylpenicillin.This crude product (15.8 g) in water (360 ml) was added to a
prehydrogenated suspension of 10% palladium on charcoal (4 g) in water
(400 ml), and hydrogenation was continued for 30 minutes. The catalyst was
removed and the filtrate was adjusted to pH 7.5 with sodium bicarbonate,
then evaporated at low temperature and pressure. The residue was purified by
chromatography on a column of cellulose powder, eluting first with
butanol/ethanol/water mixture and then with acetone/isopropanol/water. The
main fraction was evaporated at low temperature and pressure to give a 32%
yield of the sodium salt of alpha-carboxybenzylpenicillin as a white powder.
The product was estimated by monometric assay with penicillinase to be 58%
pure.
Therapeutic Function
Antibacterial
Antimicrobial activity
α-Carboxybenzylpenicillin; the first antipseudomonal penicillin
to be developed. A semisynthetic carboxypenicillin supplied
as the disodium salt for parenteral administration. The two
esterified prodrug formulations, carindacillin (carbenicillin
indanyl sodium) and carfecillin (carbenicillin carboxyphenyl
ester) are no longer available.
It is the least active of the group 5 agents, even against
Ps. aeruginosa (MIC 64 mg/L) with notably reduced activity
against Gram-positive cocci. It is labile to many plasmidmediated
β-lactamases, but is comparatively stable to class C
chromosomal β-lactamases (pp. 228–230). Synergy is demonstrable
with aminoglycosides against Ps. aeruginosa and other
Gram-negative bacteria.
It is not orally absorbed, except in esterified form. A 1 g
intramuscular injection achieves a plasma peak concentration
of 20–30 mg/L after 0.5–1.5 h. The half-life is around 1 h.
Plasma protein binding is 50–60%.
The drug is distributed in the extracellular fluid, providing
concentrations up to 60% of those of the plasma. In patients
with cystic fibrosis sputum concentrations may not reach
inhibitory levels for Ps. aeruginosa. It does not cross the normal
meninges but levels of up to 50% of those of the plasma
can be found in patients with meningitis. Around 80% of the dose appears as unchanged drug in the urine, producing very
high levels (2–4 g/L). It is more rapidly disposed of in patients
with cystic fibrosis.
Hypersensitivity reactions may occur, but these are less
frequent and severe than those associated with benzylpenicillin.
High blood levels sometimes cause a coagulation defect
that has occasionally progressed to life-threatening bleeding
in patients with impaired excretion while receiving 500 mg/kg
per day or more. Reversible abnormalities of liver function
apparently occur more commonly than with other antipseudomonal
penicillins. Since large doses of the drug have
to be used, convulsions can occur (as with other penicillins;
p. 203) and, being administered as the disodium salt, electrolyte
disturbances can result. It was formerly
used for treatment
of serious infections, especially those involving Ps. aeruginosa.
It has extremely limited availability.
Biological Activity
carbenicillin is broad-spectrum semisynthetic penicillin derivative used parenterally.
Synthesis
Carbenicillin, [2S-(2α,5α,6β)]-3,3-dimethyl-7-oxo-6-(2-carboxy-2-
phenylacetamido)-4-thia-1-azabicyclo[3.2.0]-heptan-2-carboxylic acid (32.1.1.32), is synthesized by direct acylation of 6-APA in the presence of sodium bicarbonate by
phenylmalonic acid monobenzyl ester chloride, which forms the benzyl ester of carbenicillin (32.1.1.31), the hydrogenolysis of which using palladium on carbon or calcium carbonate as catalyst gives the desired product (32.1.1.32).
Check Digit Verification of cas no
The CAS Registry Mumber 4697-36-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,6,9 and 7 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 4697-36:
(6*4)+(5*6)+(4*9)+(3*7)+(2*3)+(1*6)=123
123 % 10 = 3
So 4697-36-3 is a valid CAS Registry Number.
InChI:InChI=1/C17H18N2O6S/c1-17(2)11(16(24)25)19-13(21)10(14(19)26-17)18-12(20)9(15(22)23)8-6-4-3-5-7-8/h3-7,9-11,14H,1-2H3,(H,18,20)(H,22,23)(H,24,25)/t9?,10-,11+,14-/m1/s1
4697-36-3Relevant articles and documents
Epimerization kinetics of moxalactam, its derivatives, and carbenicillin in aqueous solution
Hashimoto,Tanaka
, p. 68 - 71 (1985)
The mechanism of the epimerization of moxalactam was studied by measuring the rate of epimerization after deuteration of the C-7 side-chain chiral carbon, introduction of different substituents on the side chain, and variation of the ring system. Deuteration slowed the epimerization rate considerably. The rate was also influenced by the choice of the ring system and the substituent on the C-7 side-chain chiral carbon. When the penicillin ring system with the 2-carboxy-2-phenylacetamide was studied, the epimerization rate decreased indicating that the same ring system needed to be used throughout the epimerization studies. Thus, experiments were conducted with different substituents replacing the phenolic group at the C-7 side-chain chiral carbon of moxalactam. The epimerization rate decreased in the substituent order thienyl, phenyl, 4-hydroxyphenyl, the ionized form of 4-hydroxyphenyl, and ethyl. These results showed that dehydrogenation of the chiral carbon seems to be the rate-determining step and that the stronger the electron-donating effect of the substituent, the slower the epimerization rate becomes.
Method of using deuterated calcium channel blockers
-
, (2008/06/13)
Therapeutic methods and compositions using deuterated enriched 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester and other deuterated dihydropyridine compounds are described. The deuterated compounds exhibit enhanced efficacy in blocking calcium channels over non-deuterated dihydropyridines.
Prodrug derivatives of carboxylic acid drugs
-
, (2008/06/13)
Novel ester derivatives of carboxylic acid medicaments of formula (I), wherein R--COO--represents the acyloxy residue of a carboxylic acid drug or medicament, n is an integrer from 1 to 3, and R1 and R2 are the same or different and are selected from a group consisting of an alkyl, an alkenyl, an aryl, an aralkyl, a cycloalkyl and which group may be unsubstituted or substituted, or R1 and R2 together with the N forms a 4-, 5-, 6- or 7-membered heterocyclic ring, which in addition to the nitrogen atom may contain one or two further heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and which heterocyclic group may be substituted. These compounds are highly biolabile prodrug forms of the corresponding carboxylic acid compounds and are highly susceptible to undergoing enzymatic hydrolysis in vivo whereas they are highly stable in aqueous solution. The novel derivatives are less irritating to mucosa than the parent carboxylic acids and may provide an improved bio-availability of the drugs.
